problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201157630-34problendo-4629Research ArticleСтатьиArticlesЛевитра: многогранность действия, перспективы примененияLevitra: multiple action, prospects for applicationVertkinA L-MorgunovL Iu-ZviagintsevaE I-201115122011576ТОМ 57, №6 (2011)3034Copyright © Vertkin A.L., Morgunov L.I., Zviagintseva E.I., 20112011Vertkin A.L., Morgunov L.I., Zviagintseva E.I.Vertkin A.L., Morgunov L.I., Zviagintseva E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/4629

Варденафил (Левитра) - ингибитор фосфодиэстеразы 5-го типа, традиционно используемый для лечения эректильной дисфункции. Применение Левитры при сопутствующей кардиоваскулярной патологии, а также в комбинированной терапии, безопасно, однако изучено не в полной мере. Перспективы применения Левитры при лечении различных соматических заболеваний достаточно широки.

Vardenafil (Levitra) is a phosphodiesterase type V inhibitor traditionally used for the treatment of erectile dysfunction. The use of Levitra by the subjects free of a concomitant pathology (including combined therapy) is believed to be safe, however its action awaits further investigation. It is expected that Levitra will find a wider application in the future for the management of various somatic disorders.

Левитраварденафилэректильная дисфункциябезопасностьсердечно-сосудистая системаLevitravardenafilerectile dysfunctionsafetycardiovascular systemReferencesPorst H., Sharlip I. History and epidemiology of male sexual dysfunction. Standart practice in sexual medicine. Eds. H. Porst, I. Sharlip. J Buvat 2006; 43-48.Porst H., Sharlip I. History and epidemiology of male sexual dysfunction. Standart practice in sexual medicine. Eds. H. Porst, I. Sharlip. J Buvat 2006; 43-48.Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453-459.Corbin J.D., Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002; 56: 453-459.Van Ahlen H., Zumbé J., Stauch K., Hanisch J.U. The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med 2010; 7: 9: 3161-3169.Van Ahlen H., Zumbé J., Stauch K., Hanisch J.U. The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med 2010; 7: 9: 3161-3169.Reffelmann T., Kloner R.A. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2006; 2: 4: 447-455.Reffelmann T., Kloner R.A. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag 2006; 2: 4: 447-455.Rosen R.C., Jackson G., Kostis J.B. Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep 2006; 7: 6: 490-496.Rosen R.C., Jackson G., Kostis J.B. Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep 2006; 7: 6: 490-496.Guazzi M., Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007; 14: 20: 2181-2191.Guazzi M., Samaja M. The role of PDE5-inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 2007; 14: 20: 2181-2191.Vlachopoulos C., Ioakeimidis N., Rokkas K., Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009; 6: 3: 658-674.Vlachopoulos C., Ioakeimidis N., Rokkas K., Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009; 6: 3: 658-674.Szabó G., Radovits T., Veres G. et al. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 2009; 36: 4: 657-664.Szabó G., Radovits T., Veres G. et al. Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass. Eur J Cardiothorac Surg 2009; 36: 4: 657-664.Kapur V., Chien C.V., Fuess J.E., Schwarz E.R. The relationship between erectile dysfunction and cardiovascular disease. The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008; 9: 3: 187-195.Kapur V., Chien C.V., Fuess J.E., Schwarz E.R. The relationship between erectile dysfunction and cardiovascular disease. The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. Rev Cardiovasc Med 2008; 9: 3: 187-195.Li H.J. Efficacy and safety of vardenafil in the treatment of erectile dysfunction in men with hypertension. Zhonghua Nan Ke Xue 2006; 12: 10: 953-956.Li H.J. Efficacy and safety of vardenafil in the treatment of erectile dysfunction in men with hypertension. Zhonghua Nan Ke Xue 2006; 12: 10: 953-956.Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005; 26: 96: 12B: 32M-36M.Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005; 26: 96: 12B: 32M-36M.Miner M.M., Barnes A., Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010; 7: 5: 1937-1947.Miner M.M., Barnes A., Janning S. Efficacy of phosphodiesterase type 5 inhibitor treatment in men with erectile dysfunction and dyslipidemia: a post hoc analysis of the vardenafil statin study. J Sex Med 2010; 7: 5: 1937-1947.Vardi M., Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; 24: 1: CD002187.Vardi M., Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; 24: 1: CD002187.Rubio-Aurioles E., Porst H., Eardley I., Goldstein I. Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 6: 1034-1037.Rubio-Aurioles E., Porst H., Eardley I., Goldstein I. Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 6: 1034-1037.Schwarz E.R., Kapur V., Rodriguez J., Rastogi S. et al. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007; 19: 2: 139-148.Schwarz E.R., Kapur V., Rodriguez J., Rastogi S. et al. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007; 19: 2: 139-148.Aizawa K., Hanaoka T., Kasai H. et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29: 2: 123-128.Aizawa K., Hanaoka T., Kasai H. et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29: 2: 123-128.Deibert P., Schumacher Y.O., Ruecker G., Opitz O.G. et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver - results of a pilot study. Aliment Pharmacol Ther 2006; 1: 23: 1: 121-128.Deibert P., Schumacher Y.O., Ruecker G., Opitz O.G. et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver - results of a pilot study. Aliment Pharmacol Ther 2006; 1: 23: 1: 121-128.Cheon Y.K., Cho Y.D., Moon J.H. et al. Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009; 69: 6: 1111-1116.Cheon Y.K., Cho Y.D., Moon J.H. et al. Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. Gastrointest Endosc 2009; 69: 6: 1111-1116.Corona G., Razzoli E., Forti G., Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Inv 2008; 31: 9: 799-808.Corona G., Razzoli E., Forti G., Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Inv 2008; 31: 9: 799-808.Ng C.F., Wong A., Cheng C.W., Chan E.S., Wong H.M., Hou S.M. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol 2008; 180: 3: 1042-1046.Ng C.F., Wong A., Cheng C.W., Chan E.S., Wong H.M., Hou S.M. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol 2008; 180: 3: 1042-1046.Kloner R.A. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005; 96: 12B: 42M-46M.Kloner R.A. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005; 96: 12B: 42M-46M.Shabsigh R. The role of testosterone in the cavernous tissues and its neural supply. World J Urol 1997; 15: 21-26.Shabsigh R. The role of testosterone in the cavernous tissues and its neural supply. World J Urol 1997; 15: 21-26.Corona G., Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7: 1: 46-56.Corona G., Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010; 7: 1: 46-56.Van der Made F., Bloemers J., Yassem W.E. et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med 2009; 6: 3: 777-790.Van der Made F., Bloemers J., Yassem W.E. et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med 2009; 6: 3: 777-790.

The authors declare that there are no conflicts of interest present.